Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
March 19 2020 - 6:00AM
Business Wire
Athersys Announces Inducement Grant Under
Nasdaq Listing Rule 5635(c)(4)
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX)
announced today the addition of Ms. Maia Hansen, an experienced
leader in operations and supply chain management, to the Athersys
leadership team. Ms. Hansen has been appointed Senior Vice
President, Operations and Supply Chain to help establish and manage
a sustainable supply chain built to enable reliable, cost-effective
and best in class commercial manufacturing and product distribution
capabilities to support commercial success. Ms. Hansen will have
overall responsibility for supply chain strategy, related
operations and capability building. She will work closely with Mr.
Greg Liposky, Senior Vice President and Head of Manufacturing, and
the rest of the executive team to establish a premier product
supply organization and capabilities oriented to sustainable, large
scale commercialization.
Ms. Hansen has extensive operations and supply chain experience
in the pharmaceutical, medical device and consumer health sectors.
Prior to joining Athersys, Ms. Hansen was a Senior Partner at
McKinsey & Company, a global management consulting firm. She
worked with clients around the world to develop and optimize
end-to-end operations and global supply chains. Her work included
the development of operations and supply chain strategy, capability
building, manufacturing optimization, go-to-market effectiveness,
and digital and analytics. In addition, she has worked with clients
to connect operations with corporate strategy and product
development. These projects included the development and execution
of a manufacturing production system across a large, global network
for a leading pharmaceutical company. Her work also enabled a
health care company to improve collaboration between its product
development team and outside suppliers to improve consumer
experience and increase both productivity and margins. She was a
leader within McKinsey’s Operations practice and led the operations
transformation and capability building service line to ensure
impact across large-scale operations. In addition, Ms. Hansen
served as the Managing Partner of McKinsey’s Cleveland office.
“We are very excited to have Maia join the leadership team at
Athersys. As we’ve described previously, we are committed to
building a world-class organization that is well-positioned to
deliver on the promise of our innovative regenerative medicine
technology, and to helping advance the boundaries of medicine in
areas where there is a substantial unmet medical need. Maia brings
tremendous experience and capabilities, and she will play an
important role as we move forward,” commented Dr. Gil Van Bokkelen,
Chairman and CEO at Athersys.
“I am excited to join Athersys and look forward to working with
the team to establish world-class capabilities, strategy and
execution to ensure and optimize the supply of our cell therapy
products to patients in need. We have the opportunity to bring a
whole new class of therapy to help people with serious medical
conditions, and I look forward to helping enable this mission,”
concluded Ms. Hansen.
Athersys also announced today that, the Company made an
inducement grant to Ms. Hansen, the newly appointed Senior Vice
President, Operations and Supply Chain. The Company’s Board of
Directors approved, pursuant to Rule 5635(c)(4) of the Nasdaq Stock
Market Listing Rules, the grant of an inducement equity award in
the form of a nonqualified stock option to purchase 400,000 shares
of the Company’s common stock. The option was granted outside of
Athersys’ 2019 Equity and Incentive Compensation Plan as an
inducement material to Ms. Hansen’s acceptance of employment with
the Company.
The stock option has an exercise price equal to the closing
price of Athersys’ common stock on the grant date of March 16,
2020, Ms. Hansen’s first day of employment. The option has up to a
ten-year term and vests over four years, with 25% of the award
vesting on March 16, 2021, and the remainder vesting in equal
quarterly installments over the remaining three years, subject to
Ms. Hansen’s continued service with Athersys through the applicable
vesting dates (except under certain conditions regarding her death
or disability or a change in control of Athersys).
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem® cell therapy product, a patented, adult-derived
"off-the-shelf" stem cell product, initially for disease
indications in the neurological, inflammatory and immune,
cardiovascular and other critical care indications and has several
ongoing clinical trials evaluating this potential regenerative
medicine product. Athersys has forged strategic partnerships and a
broad network of collaborations to further advance the MultiStem
cell therapy toward commercialization. More information is
available at www.athersys.com. Follow Athersys on Twitter at
www.twitter.com/athersys.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200319005152/en/
Ivor Macleod Chief Financial Officer Tel: (216) 431-9900
ir@athersys.com Karen Hunady Director of Corporate Communications
& Investor Relations Tel: (216) 431-9900 khunady@athersys.com
David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858)
717-2310 David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024